Investor Presentaiton

Company overview Financial performance Oncology Immunology Financial review 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Neuroscience Respiratory Disease Cardio-Renal Global Health Biosimilars denosumab - anti RANKL mAb NCT03974100 (CGP24112301) Osteoporosis (same as originator) Indication Phase Phase 3 Patients 522 Primary Outcome Measures Arms Percent change from baseline (%CfB) in lumbar spine Bone Mineral Density Intervention GP2411 60 mg/mL subcutaneous injection every 6 months ProliaⓇ 60 mg/mL subcutaneous injection every 6 months Postmenopausal women with osteoporosis Target Patients Read-out Milestone(s) Publication 2022 Study data publications expected for 2024 and beyond. The overall study design will be published at WCO and ECTS congresses 2020. 106 Investor Relations | Q2 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation